União Europeia - inglês - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptin - diabetes mellitus, type 2 - drugs used in diabetes - trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults:as monotherapyin patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.as combination therapyin combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

União Europeia - inglês - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin, linagliptin - diabetes mellitus, type 2 - drugs used in diabetes - glyxambi, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (su) and one of the monocomponents of glyxambi do not provide adequate glycaemic control;when already being treated with the free combination of empagliflozin and linagliptin.

União Europeia - inglês - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - dabigatran etexilate mesilate - arthroplasty, replacement; venous thromboembolism - antithrombotic agents - pradaxa 75 mgprimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.pradaxa 110 mgprimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischemic attack (tia); age ≥ 75 years; heart failure (nyha class ≥ ii); diabetes mellitus; hypertension.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.pradaxa 150 mgprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischemic attack (tia); age ≥ 75 years; heart failure (nyha class ≥ ii); diabetes mellitus; hypertension.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

Israel - inglês - Ministry of Health

boehringer ingelheim israel ltd. - olodaterol as hydrochloride; tiotropium bromide as monohydrate - solution for inhalation - olodaterol as hydrochloride 2.5 mcg; tiotropium bromide as monohydrate 2.5 mcg - vilanterol and umeclidinium bromide - spiolto respimat is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Cingapura - inglês - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - linagliptin; metformin 779.83mg eqv. metformin hydrochloride - tablet, film coated - 2.500mg - linagliptin 2.500mg; metformin 779.83mg eqv. metformin hydrochloride 1000.000mg

Cingapura - inglês - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - linagliptin; metformin 389.91mg eqv. metformin hydrochloride - tablet, film coated - 2.500mg - linagliptin 2.500mg; metformin 389.91mg eqv. metformin hydrochloride 500.000mg

Cingapura - inglês - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - linagliptin; metformin 662.85mg eqv. metformin hydrochloride - tablet, film coated - 2.500mg - linagliptin 2.500mg; metformin 662.85mg eqv. metformin hydrochloride 850.000mg

Cingapura - inglês - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - nintedanib ethanesulfonate 120.40 eqv nintedanib - capsule, liquid filled - nintedanib ethanesulfonate 120.40 eqv nintedanib 100mg

Cingapura - inglês - HSA (Health Sciences Authority)

boehringer ingelheim singapore pte. ltd. - nintedanib ethanesulfonate 180.60mg eqv nintedanib - capsule, liquid filled - nintedanib ethanesulfonate 180.60mg eqv nintedanib 150mg

Malásia - inglês - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

boehringer ingelheim (malaysia) sdn. bhd. - nintedanib esilate -